Nonpurulent cellulitis | | |
Empiric therapy for group A streptococcus | | |
• Cephalexin | 500 mg orally, 4 times daily | 50–100 mg/kg orally, divided 4 times daily |
Empiric therapy for group A streptococcus and MRSA | | |
• Cephalexin and 1 of the following:
-TMP-SMX* or -doxycycline†
| 500 mg orally, 4 times daily, and 1 of the following:
1 to 2 DS TMP-SMX tablets orally, twice daily,‡ or 100 mg of doxycycline orally, twice daily
| 50–100 mg/kg orally, divided 4 times daily, and 1 of the following:
8 to 12 mg/kg of TMP-SMX orally, divided twice daily, or 4 mg/kg of doxycycline orally, divided twice daily
|
Purulent cellulitis | | |
Empiric therapy for MSSA | | |
• Cephalexin | 500 mg orally, 4 times daily | 50–100 mg/kg orally, divided 4 times daily |
• Cloxacillin | 500 mg orally, 4 times daily | 50 mg/kg orally, divided 4 times daily |
Empiric therapy for community-associated MRSA | | |
• TMP-SMX* | 1 to 2 DS tablets orally, twice daily‡ | 8–12 mg/kg orally, divided twice daily |
• Doxycycline† | 100 mg orally, twice daily | 4 mg/kg orally, divided twice daily |